David Mu

List of Publications by Year
in descending order

53 papers	10,712 citations	101543 36 h-index	175258 52 g-index
53 all docs	53 docs citations	53 times ranked	13900 citing authors

#	Article	IF	Citations
1	Connecting Cholesterol Efflux Factors to Lung Cancer Biology and Therapeutics. International Journal of Molecular Sciences, 2021, 22, 7209.	4.1	6
2	Mechanistic Study of TTF-1 Modulation of Cellular Sensitivity to Cisplatin. Scientific Reports, 2019, 9, 7990.	3.3	3
3	Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism. Oncogene, 2018, 37, 3290-3300.	5.9	9
4	Roles of Thyroid Transcription Factor 1 in Lung Cancer Biology. Vitamins and Hormones, 2018, 106, 517-544.	1.7	16
5	Thyroid Transcription Factorâ€1 modulation of secretome alters sensitivity to cisplatin in lung cancer. FASEB Journal, 2018, 32, lb434.	0.5	0
6	Thyroid Transcription Factor 1 Reprograms Angiogenic Activities of Secretome. Scientific Reports, 2016, 6, 19857.	3.3	13
7	Mnk2 Alternative Splicing Modulates the p38-MAPK Pathway and Impacts Ras-Induced Transformation. Cell Reports, 2014, 7, 501-513.	6.4	92
8	Tight junction proteins: From barrier to tumorigenesis. Cancer Letters, 2013, 337, 41-48.	7.2	178
9	MicroRNA-33a Mediates the Regulation of High Mobility Group AT-Hook 2 Gene (HMGA2) by Thyroid Transcription Factor 1 (TTF-1/NKX2â€“1). Journal of Biological Chemistry, 2013, 288, 16348-16360.	3.4	56
10	The splicing factor <scp>SRSF6</scp> is amplified and is an oncoprotein inÂlung and colon cancers. Journal of Pathology, 2013, 229, 630-639.	4.5	126
11	The Complexity of Thyroid Transcription Factor 1 with Both Pro- and Anti-oncogenic Activities. Journal of Biological Chemistry, 2013, 288, 24992-25000.	3.4	29
12	Two Distinct Categories of Focal Deletions in Cancer Genomes. PLoS ONE, 2013, 8, e66264.	2.5	34
13	MiR-365 regulates lung cancer and developmental gene thyroid transcription factor 1. Cell Cycle, 2012, 11, 177-186.	2.6	74
14	Occludin Is a Direct Target of Thyroid Transcription Factor-1 (TTF-1/NKX2â€“1). Journal of Biological Chemistry, 2012, 287, 28790-28801.	3.4	43
15	MicroRNAs and lung cancers: from pathogenesis to clinical implications. Frontiers of Medicine, 2012, 6, 134-155.	3.4	46
16	Cooperation between Rb and Arf in suppressing mouse retinoblastoma. Journal of Clinical Investigation, 2012, 122, 1726-1733.	8.2	23
17	miR-17â^¼92 cooperates with RB pathway mutations to promote retinoblastoma. Genes and Development, 2011, 25, 1734-1745.	5.9	164
18	Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes and Development, 2010, 24, 837-852.	5.9	174

#	Article	IF	Citations
19	Characterizing the developmental pathways TTF-1 , NKX2â€“8 , and PAX9 in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 5312-5317.	7.1	50
20	Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. International Journal of Cancer, 2008, 123, 2041-2047.	5.1	42
21	Neurofibromin 1 (NF1) Defects Are Common in Human Ovarian Serous Carcinomas and Co-occur with TP53 Mutations. Neoplasia, 2008, 10, 1362-IN9.	5.3	74
22	Genetic similarities between organogenesis and tumorigenesis of the lung. Cell Cycle, 2008, 7, 200-204.	2.6	19
23	Role of the chromobox protein CBX7 in lymphomagenesis. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 5389-5394.	7.1	150
24	Oncogenic cooperation and coamplification of developmental transcription factor genes in lung cancer. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 16663-16668.	7.1	203
25	Murine bilateral retinoblastoma exhibiting rapid-onset, metastatic progression and N-myc gene amplification. EMBO Journal, 2007, 26, 784-794.	7.8	69
26	The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology, 2007, 14, 185-193.	8.2	786
27	Identification and Validation of Oncogenes in Liver Cancer Using an Integrative Oncogenomic Approach. Cell, 2006, 125, 1253-1267.	28.9	989
28	Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas. Leukemia, 2006, 20, 539-542.	7.2	15
29	Gene Mutations and Genomic Rearrangements in the Mouse as a Result of Transposon Mobilization from Chromosomal Concatemers. PLoS Genetics, 2006, 2, e156.	3.5	90
30	Identification of alterations in DNA copy number in host stromal cells during tumor progression. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19848-19853.	7.1	55
31	Translocation t(14;18) and gain of chromosome 18/BCL2: effects on BCL2 expression and apoptosis in B-cell non-Hodgkin's lymphomas. Leukemia, 2005, 19, 2313-2323.	7.2	27
32	A microRNA polycistron as a potential human oncogene. Nature, 2005, 435, 828-833.	27.8	3,390
33	Genomic amplification and oncogenic properties of the KCNK9 potassium channel gene. Cancer Cell, 2003, 3, 297-302.	16.8	229
34	Oncogenic potential of TASK3 (Kcnk9) depends on K+ channel function. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7803-7807.	7.1	152
35	DNA Interstrand Cross-Links Induce Futile Repair Synthesis in Mammalian Cell Extracts. Molecular and Cellular Biology, 2000, 20, 2446-2454.	2.3	115
36	Model for XPC-independent Transcription-coupled Repair of Pyrimidine Dimers in Humans. Journal of Biological Chemistry, 1997, 272, 7570-7573.	3.4	91

#	Article	IF	Citations
37	Characterization of Reaction Intermediates of Human Excision Repair Nuclease. Journal of Biological Chemistry, 1997, 272, 28971-28979.	3.4	151
38	DNA Excision Repair Assays. Progress in Molecular Biology and Translational Science, 1997, 56, 63-81.	1.9	7
39	Repair of Cisplatinâ^'DNA Adducts by the Mammalian Excision Nucleaseâ€. Biochemistry, 1996, 35, 10004-10013.	2.5	316
40	Reaction Mechanism of Human DNA Repair Excision Nuclease. Journal of Biological Chemistry, 1996, 271, 8285-8294.	3.4	320
41	Overproduction, Purification, and Characterization of the XPC Subunit of the Human DNA Repair Excision Nuclease. Journal of Biological Chemistry, 1996, 271, 19451-19456.	3.4	138
42	Replication Protein A Confers Structure-specific Endonuclease Activities to the XPF-ERCC1 and XPG Subunits of Human DNA Repair Excision Nuclease. Journal of Biological Chemistry, 1996, 271, 11047-11050.	3.4	178
43	Functional complementation of xeroderma pigmentosum complementation group E by replication protein A in an in vitro system.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 5014-5018.	7.1	72
44	[8] Cloning of mammalian topa quinone-containing enzymes. Methods in Enzymology, 1995, 258, 114-122.	1.0	1
45	Reconstitution of Human DNA Repair Excision Nuclease in a Highly Defined System. Journal of Biological Chemistry, 1995, 270, 2415-2418.	3.4	431
46	The General Transcription-Repair Factor TFIIH Is Recruited to the Excision Repair Complex by the XPA Protein Independent of the TFIIE Transcription Factor. Journal of Biological Chemistry, 1995, 270, 4896-4902.	3.4	180
47	Human DNA Repair Excision Nuclease. Journal of Biological Chemistry, 1995, 270, 20862-20869.	3.4	188
48	Quinoenzymes in Biology. Annual Review of Biochemistry, 1994, 63, 299-344.	11.1	328
49	Human andE.coliexcinucleases are affected differently by the sequence context of acetylaminofluoreneâ€“guanine adduct. Nucleic Acids Research, 1994, 22, 4869-4871.	14.5	39
50	A new redox cofactor in eukaryotic enzymes: 6-hydroxydopa at the active site of bovine serum amine oxidase. Science, 1990, 248, 981-987.	12.6	685
51	Preparation of molybdenum-.eta.3-pentadienyl complexes: structural characterization of a delocalized pentadienyl ligand in anti-.eta.3 geometry. Organometallics, 1989, 8, 402-407.	2.3	25
52	Preparation and properties of molybdenum-pentadienyl complexes: a facile .eta.5 .dblarw. .eta.3 reversible interconversion for a pentadienyl ligand. Organometallics, 1989, 8, 2248-2252.	2.3	12
53	Reaction of iron-.eta.1-dienyl complexes with dienophiles. X-ray structures of the [4 + 2] cycloaddition adducts. Organometallics, 1988, 7, 1155-1161.	2.3	9